Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273224 | 0.97 | — | — | |
| SCHEMBL18738 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL28075387 | 0.93 | — | — | |
| Iodide SCHEMBL15299863 | 0.93 | — | — | |
| SCHEMBL288074 | 0.90 | LMNA (0.43) | — | |
| Acetic Acid SCHEMBL27573497 | 0.90 | FFAR3 (0.44) | — | |
| Cyclohexane SCHEMBL10406918 | 0.88 | LMNA (0.42) | — | |
| SCHEMBL3640760 | 0.88 | LMNA (0.42) | — | |
| Benzene SCHEMBL4101064 | 0.88 | LMNA (0.45) | — | |
| Acetic Acid SCHEMBL28859591 | 0.85 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112423758-A | Adenosine receptor binding compounds | 尼康治疗公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-9603832-B2 | Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-9585869-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-9474738-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| US-9474739-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| US-9474737-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| EP-3045445-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2016-07-20 | — | — | EP | disclosed |
| CN-101263131-A | Urea glucokinase activators | NOVO NORDISK AS (US) | 2008-09-10 | — | — | CN | disclosed |
| CN-101238602-A | Electrode electrolyte for use in solid polymer fuel cell | JSR CORP (JP) | 2008-08-06 | — | — | CN | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1463947-A4 | METHOD FOR REDUCING NON-SPECIFIC AGGREGATION OF LATEX MICROPARTICLES IN THE PRESENCE OF SERUM OR PLASMA | BECKMAN COULTIER INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6927071-B2 | Method for reducing non-specific aggregation of latex microparticles in the presence of serum or plasma | BECKMAN COULTER, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1463947-A2 | METHOD FOR REDUCING NON-SPECIFIC AGGREGATION OF LATEX MICROPARTICLES IN THE PRESENCE OF SERUM OR PLASMA | Beckman Coultier, Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003050292-A2 | METHOD FOR REDUCING NON-SPECIFIC AGGREGATION OF LATEX MICROPARTICLES IN THE PRESENCE OF SERUM OR PLASMA | BECKMAN COULTIER, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0386053-A1 | NON-ANTICOAGULANT HEPARAN SULFATE, PROCESS FOR EXTRACTION FROM ORGANS, AND PHARMACEUTICAL COMPOSITIONS THEREOF. | OPOCRIN SPA (IT) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004328-A1 | NON-ANTICOAGULANT HEPARAN SULFATE, PROCESS FOR EXTRACTION FROM ORGANS, AND PHARMACEUTICAL COMPOSITIONS THEREOF | OPOCRIN S.P.A. LABORATORIO FARMACOBIOLOGICO (IT) | 1989-05-18 | — | — | WO | disclosed |